- World Pharma News Home » Financial » Nycomed's preclinical anti-cancer program sold to Bayer Schering Pharma
(a free service delivered by FeedBurner)
Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomed's strategic decision not to further invest in oncology R&D activities. As the final step in the divestment of its Oncology portfolio, Nycomed agreed with Bayer Schering Pharma on the sale of a kinase inhibitor program, targeting a key growth and survival pathway in cancer. The agreement comprises two potential drug candidates and an extensive back-up program.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments